Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

LINAC spend cuts New Zealand's radiotherapy waits - more to come:

This article was originally published in Clinica

Executive Summary

New Zealand has reported a drop in post-operative radiology waiting times from 18 weeks to 12, thanks in large measure to its investment in linear accelerators, but the government acknowledges that more needs to be done. "New LINACs are being provided on a rolling programme," said the minister of health, Annette King, adding that: "New Zealand's cancer infrastructure remains fragile because of the time it takes to train staff." The success of the programme is being attributed mainly to the NZ$40m investment of the first phase of the Cancer Control Strategy Action Plan (see Clinica No 1156, p 14). A measure of its success is that patients are not having to be sent to Australia for radiotherapy.

You may also be interested in...



Jazz And PharmaMar’s Zepzelca Hits Buffers In ATLANTIS Study

Jazz and PharmaMar need to see what further data will be needed to convert their FDA authorization into a full approval following disappointing results in the ATLANTIS Phase III trial.

Experts Defend UK Agency Over Rapid Authorization Of COVID-19 Vaccine

As arguments rage over whether the UK regulator has rushed its assessment of the Pfizer/BioNTech vaccine, the European Medicines Agency explains why its conditional marketing authorization approach is taking a little longer.

Public Health Threat For EU Patients If IVDR Implementation Issues Remain Unaddressed

The IVDR implementation schedule is problematic. European notified bodies say solutions must be grasped if public health is not to suffer.

Topics

UsernamePublicRestriction

Register

OM002409

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel